Optimer Pharmaceuticals, Inc. launched Dificid (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in patients 18 years of age and older.
gIcare Pharma Inc. announced the closing of a $7 million Series A financing.
GenomeQuest and Pathogenica have announced a strategic partnership to offer discovery services in infectious disease research, including the interaction between the human microbiome and human genome.
A new study reveals that just as different soldiers in the field have different jobs, subsets of a type of immune cell that polices the barriers of the body can promote unique and opposite immune responses against the same type of infection.
Inotek Pharmaceuticals Corp. announced the successful completion of two of three stages of a multiple-dose Phase 2b clinical trial of its eye-drop candidate, INO-8875, for patients with glaucoma or ocular hypertension.
In January 2008, manufacturers voluntarily removed over-the-counter infant cough and cold products from the market due to safety concerns. Later, manufacturers also re-labeled these cough and cold products to state: “do not use in children under 4 years of age.”
Swiss maker of cancer-fighting drugs Roche Holding AG announced a 5 percent drop in net profits during the first six months of the year, blaming Switzerland's strong currency for dampening results.
Human Genome Sciences Inc. reported a larger second-quarter loss as it recorded higher expenses related to its lupus drug Benlysta and lower revenue compared to the year-ago period when it received payments related to an agreement with Novartis AG.
Bristol-Myers Squibb Co. has agreed to buy the privately held Amira Pharmaceuticals in an all-cash deal that could be worth $475 million counting milestone payments.
Bruker announced the release of the SCION TQ triple quadrupole mass spectrometer for gas chromatography detection. These instruments are designed especially to enhance data quality and productivity.
Beckman Coulter Genomics offers an automated, target capture sequencing service for targeted next generation sequencing.
Researchers at The Scripps Research Institute have developed a vaccine against a heroin high and have proven its therapeutic potential in animal models.
Allon Therapeutics Inc. announced findings that 12 weeks of treatment with davunetide, the company’s lead product, appears to prevent cortical thinning of important parts of the brains of schizophrenia patients.
Cellectis bioresearch and Lonza announce that they have reached a milestone in the development of a newly bioengineered cell line.
GNS Healthcare, Inc. (GNS) and the National Cancer Institute (NCI) will develop a supercomputing platform that can uncover cause-and-effect mechanisms for lung cancer hidden in data sets assembled from imaging, genetics, pathology, and other areas.